Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient.
We report a stem cell transplant recipient who developed human herpesvirus 6 encephalitis. Human herpesvirus 6 load indicated massive intrathecal viral replication. Administration of cidofovir followed by foscarnet was associated with total clearance of human herpesvirus 6 infection. Cidofovir and foscarnet combination therapy may be beneficial for reducing mortality of (neutropenic) stem cell transplant recipients with human herpesvirus 6 encephalitis.
Pöhlmann
Christoph
C
Institut für Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Schetelig
Johannes
J
Reuner
Ulrike
U
Bornhäuser
Martin
M
Illmer
Thomas
T
Kiani
Alexander
A
Ehninger
Gerhard
G
Jacobs
Enno
E
Rohayem
Jacques
J
D000998:Antiviral Agents / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D018792:Encephalitis, Viral / Q000188:drug therapy*; D017245:Foscarnet / Q000627:therapeutic use*; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D015654:Herpesvirus 6, Human / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D019349:Roseolovirus Infections / Q000188:drug therapy* / Q000209:etiology; D019562:Viral Load
D000998:Antiviral Agents; D063065:Organophosphonates; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir